These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

127 related items for PubMed ID: 15866630

  • 1. Two doses of daclizumab with delayed introduction of low-dose tacrolimus in elderly recipients of cadaveric renal transplants from donors >55 years of age.
    Osuna A, Gentil MA, Capdevila L, Cantarell C, Mazuecos A, Pereira P, Rodríguez-Algarra G, González-Molina M, Spanish Kidney Transplant of Elderly Donor Study Group.
    Transplant Proc; 2005 Apr; 37(3):1438-40. PubMed ID: 15866630
    [Abstract] [Full Text] [Related]

  • 2. Safety and efficacy of delayed introduction of low-dose tacrolimus in elderly recipients of cadaveric renal transplants from donors over 55 years of age.
    Gentil MA, Osuna A, Capdevila L, Rodriguez-Algarra G, Cantarell C, Pereira P, González-Molina M, Spanish Kidney Transplant of Elderly Donor Study Group.
    Transplant Proc; 2003 Aug; 35(5):1706-8. PubMed ID: 12962766
    [Abstract] [Full Text] [Related]

  • 3. Use of daclizumab as initial immunosuppression in liver transplant recipients with impaired renal function.
    Emre S, Gondolesi G, Polat K, Ben-Haim M, Artis T, Fishbein TM, Sheiner PA, Kim-Schluger L, Schwartz ME, Miller CM.
    Liver Transpl; 2001 Mar; 7(3):220-5. PubMed ID: 11244163
    [Abstract] [Full Text] [Related]

  • 4. Can daclizumab reduce acute rejection and improve long-term renal function in tacrolimus-based primary renal transplant recipients?
    Cheung CY, Liu YL, Wong KM, Chan HW, Chan YH, Wong HS, Chak WL, Choi KS, Chau KF, Shek CC, Li CS.
    Nephrology (Carlton); 2008 Jun; 13(3):251-5. PubMed ID: 18221256
    [Abstract] [Full Text] [Related]

  • 5. WOFIE synergizes with calcineurin-inhibitor treatment and early steroid withdrawal in kidney transplantation.
    Dresske B, Zavazava N, Jenisch S, Exner B, Lenz P, El Mokhtari NE, Kremer B, Faendrich F.
    Transplantation; 2003 Apr 27; 75(8):1286-91. PubMed ID: 12717217
    [Abstract] [Full Text] [Related]

  • 6. Two-dose daclizumab regimen in simultaneous kidney-pancreas transplant recipients: primary endpoint analysis of a multicenter, randomized study.
    Stratta RJ, Alloway RR, Lo A, Hodge E.
    Transplantation; 2003 Apr 27; 75(8):1260-6. PubMed ID: 12717213
    [Abstract] [Full Text] [Related]

  • 7. Late evolution of kidney transplants in elderly donors and recipients receiving initial immunosuppressant treatment with daclizumab, mycophenolate mofetil, and delayed introduction of tacrolimus.
    González-Roncero FM, Gentil-Govantes MÁ, González-Molina M, Rivero M, Cantarell C, Alarcón A, Franco A, Sánchez-Plumed J, Lampreabe I, Lauzurica R, González E, Romero R, Ruiz-San Millán JC, Osuna A.
    Nefrologia; 2012 Jul 17; 32(4):446-54. PubMed ID: 22806279
    [Abstract] [Full Text] [Related]

  • 8. One-year outcomes in simultaneous kidney-pancreas transplant recipients receiving an alternative dosing regimen of daclizumab.
    Stratta RJ, Alloway RR, Lo A, Hodge EE, PIVOT Study Group.
    Transplant Proc; 2004 May 17; 36(4):1080-1. PubMed ID: 15194375
    [Abstract] [Full Text] [Related]

  • 9. No-load sirolimus with tacrolimus and steroids is safe and effective in renal transplantation.
    Tellis V, Schechner R, Mallis M, Rosegreen S, Glicklich D, Moore N, Greenstein S.
    Transplant Proc; 2005 Mar 17; 37(2):906-8. PubMed ID: 15848571
    [Abstract] [Full Text] [Related]

  • 10. Deceased donor organ transplantation with expanded criteria donors: a single-center experience from India.
    Goplani KR, Firoz A, Ramakrishana P, Shah PR, Gumber MR, Patel HV, Vanikar AV, Trivedi HL.
    Transplant Proc; 2010 Mar 17; 42(1):171-4. PubMed ID: 20172307
    [Abstract] [Full Text] [Related]

  • 11. Long-term results in renal transplant patients with allograft dysfunction after switching from calcineurin inhibitors to sirolimus.
    Bumbea V, Kamar N, Ribes D, Esposito L, Modesto A, Guitard J, Nasou G, Durand D, Rostaing L.
    Nephrol Dial Transplant; 2005 Nov 17; 20(11):2517-23. PubMed ID: 15985508
    [Abstract] [Full Text] [Related]

  • 12. The challenge of achieving target drug concentrations in clinical trials: experience from the Symphony study.
    Ekberg H, Mamelok RD, Pearson TC, Vincenti F, Tedesco-Silva H, Daloze P.
    Transplantation; 2009 May 15; 87(9):1360-6. PubMed ID: 19424036
    [Abstract] [Full Text] [Related]

  • 13. Renal function in patients with cadaveric kidney transplants treated with tacrolimus or cyclosporine.
    Gonzalez Molina M, Morales JM, Marcen R, Campistol JM, Oppenheimer F, Serón D, Gil-Vernet S, Capdevila L, Andrés A, Lampreave I, Del Castillo D, Cabello M, Burgos D, Valdés F, Anaya F, Escuín F, Arias M, Pallardó L, Bustamante J.
    Transplant Proc; 2007 Sep 15; 39(7):2167-9. PubMed ID: 17889126
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Steroid avoidance immunosuppression in low-risk kidney transplant recipients.
    Heilman RL, Mazur MJ, Reddy KS, Moss A, Post D, Mulligan D.
    Transplant Proc; 2005 May 15; 37(4):1785-8. PubMed ID: 15919466
    [Abstract] [Full Text] [Related]

  • 17. Daclizumab is associated with decreased rejection and no increased mortality in cardiac transplant patients receiving MMF, cyclosporine, and corticosteroids.
    Kobashigawa J, David K, Morris J, Chu AH, Steffen BJ, Gotz VP, Gordon RD.
    Transplant Proc; 2005 Mar 15; 37(2):1333-9. PubMed ID: 15848713
    [Abstract] [Full Text] [Related]

  • 18. Sirolimus-based triple immunosupression with antithymocyte globulin induction in expanded criteria donor kidney transplantation.
    Uslu A, Nart A, Taşli FA, Postaci H, Aykas A, Doğan M, Sahin T.
    Nephrology (Carlton); 2008 Feb 15; 13(1):80-6. PubMed ID: 18199109
    [Abstract] [Full Text] [Related]

  • 19. Renal grafts from elderly donors: histological studies and long-term results.
    Rossetti O, Soldano S, Aseni P, Colombo V, Roselli E, De Gasperi A, Sansalone CV.
    Transplant Proc; 2007 Feb 15; 39(6):1820-2. PubMed ID: 17692621
    [Abstract] [Full Text] [Related]

  • 20. Comparison of sirolimus plus tacrolimus versus sirolimus plus cyclosporine in high-risk renal allograft recipients: results from an open-label, randomized trial.
    Gaber AO, Kahan BD, Van Buren C, Schulman SL, Scarola J, Neylan JF, Sirolimus High-Risk Study Group.
    Transplantation; 2008 Nov 15; 86(9):1187-95. PubMed ID: 19005398
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 7.